Iovance Biotherapeutics Inc (DE:2LB)

FRANKFURT:2LB

2LB

Iovance Biotherapeutics

RESEARCH TOOLSreports

Iovance Biotherapeutics (2LB) Stock Forecast & Price Target

17 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2LB Analyst Ratings

Moderate Buy

7 Buy

3 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Iovance

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2LB Stock 12 Month Forecast

Average Price Target

€6.85

▲(106.19% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is €6.85 with a high forecast of €13.69 and a low forecast of €1.71. The average price target represents a 106.19% change from the last price of €3.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","14":"€14","3.5":"€3.5","10.5":"€10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.6910344,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€13.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.8455172,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7113793,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.71</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.014,3.835310338461538,4.656620676923077,5.477931015384615,6.299241353846154,7.120551692307693,7.941862030769231,8.76317236923077,9.584482707692308,10.405793046153846,11.227103384615384,12.048413723076923,12.869724061538461,{"y":13.6910344,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.014,3.308732092307692,3.6034641846153845,3.898196276923077,4.192928369230769,4.487660461538462,4.782392553846154,5.077124646153846,5.371856738461538,5.66658883076923,5.961320923076923,6.256053015384616,6.550785107692308,{"y":6.8455172,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.014,2.9137984076923074,2.8135968153846154,2.713395223076923,2.6131936307692305,2.5129920384615385,2.412790446153846,2.3125888538461536,2.2123872615384617,2.1121856692307692,2.011984076923077,1.9117824846153846,1.8115808923076924,{"y":1.7113793,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.012,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.133,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.507,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.168,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.968,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 77, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 86, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.002,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 87, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.167,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.233,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 81, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.014,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 66, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€13.69

Average Price Target€6.85

Lowest Price Target€1.71

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geulah Livshits

Chardan Capital

€21.43→€13.72

Buy

313.20%

Upside

Reiterated

04/10/26

Analysts Offer Insights on Healthcare Companies: Daré Bioscience (NASDAQ: DARE) and Iovance Biotherapeutics (NASDAQ: IOVA)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

€8.57

Buy

158.25%

Upside

Reiterated

03/30/26

Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

David Dai

UBS

€1.71→€3.43

Hold

3.30%

Upside

Assigned

03/05/26

Iovance Biotherapeutics price target raised to $4 from $2 at UBSIovance Biotherapeutics price target raised to $4 from $2 at UBS

Etzer Darout

Barclays

€8.57→€9.43

Buy

184.07%

Upside

Reiterated

02/25/26

Barclays Remains a Buy on Iovance Biotherapeutics (IOVA)

Yanan Zhu

Wells Fargo

€12

Buy

261.55%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

Asthika Goonewardene

Truist Financial

―

Hold

―

Reiterated

02/25/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Erasca (NASDAQ: ERAS) and Tempus AI, Inc. Class A (NASDAQ: TEM)

Colleen M. Kusy

Robert W. Baird

€2.57→€3.43

Hold

3.30%

Upside

Reiterated

02/25/26

Iovance Biotherapeutics price target raised to $4 from $3 at BairdIovance Biotherapeutics price target raised to $4 from $3 at Baird

Reni Benjamin

Citizens JMP

€4.29

Buy

29.12%

Upside

Upgraded

02/25/26

Iovance upgraded to Outperform from Market Perform at CitizensIovance upgraded to Outperform from Market Perform at Citizens

Tyler Van Buren

TD Cowen

€4.29

Buy

29.12%

Upside

Reiterated

02/24/26

Iovance Biotherapeutics: Strengthening Commercial Momentum and Expanding Amtagvi Runway Support Buy Rating

Joseph Pantginis

H.C. Wainwright

€7.72

Buy

132.42%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Palvella Therapeutics (NASDAQ: PVLA)

Andrea Newkirk

Goldman Sachs

€1.29→€1.71

Sell

-48.35%

Downside

Reiterated

02/05/26

Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman SachsIovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geulah Livshits

Chardan Capital

€21.43→€13.72

Buy

313.20%

Upside

Reiterated

04/10/26

Analysts Offer Insights on Healthcare Companies: Daré Bioscience (NASDAQ: DARE) and Iovance Biotherapeutics (NASDAQ: IOVA)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

€8.57

Buy

158.25%

Upside

Reiterated

03/30/26

Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

David Dai

UBS

€1.71→€3.43

Hold

3.30%

Upside

Assigned

03/05/26

Iovance Biotherapeutics price target raised to $4 from $2 at UBSIovance Biotherapeutics price target raised to $4 from $2 at UBS

Etzer Darout

Barclays

€8.57→€9.43

Buy

184.07%

Upside

Reiterated

02/25/26

Barclays Remains a Buy on Iovance Biotherapeutics (IOVA)

Yanan Zhu

Wells Fargo

€12

Buy

261.55%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

Asthika Goonewardene

Truist Financial

―

Hold

―

Reiterated

02/25/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Erasca (NASDAQ: ERAS) and Tempus AI, Inc. Class A (NASDAQ: TEM)

Colleen M. Kusy

Robert W. Baird

€2.57→€3.43

Hold

3.30%

Upside

Reiterated

02/25/26

Iovance Biotherapeutics price target raised to $4 from $3 at BairdIovance Biotherapeutics price target raised to $4 from $3 at Baird

Reni Benjamin

Citizens JMP

€4.29

Buy

29.12%

Upside

Upgraded

02/25/26

Iovance upgraded to Outperform from Market Perform at CitizensIovance upgraded to Outperform from Market Perform at Citizens

Tyler Van Buren

TD Cowen

€4.29

Buy

29.12%

Upside

Reiterated

02/24/26

Iovance Biotherapeutics: Strengthening Commercial Momentum and Expanding Amtagvi Runway Support Buy Rating

Joseph Pantginis

H.C. Wainwright

€7.72

Buy

132.42%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Palvella Therapeutics (NASDAQ: PVLA)

Andrea Newkirk

Goldman Sachs

€1.29→€1.71

Sell

-48.35%

Downside

Reiterated

02/05/26

Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman SachsIovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Iovance Biotherapeutics

3 Months

xxx

Success Rate

12/19 ratings generated profit

Average Return

+10.77%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.16% of your transactions generating a profit, with an average return of +10.77% per trade.

1 Year

Yanan ZhuWells Fargo

Success Rate

10/19 ratings generated profit

Average Return

+6.91%

reiterated a buy rating 2 months ago

Copying Yanan Zhu's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +6.91% per trade.

2 Years

xxx

Success Rate

6/19 ratings generated profit

Average Return

-17.48%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 31.58% of your transactions generating a profit, with an average return of -17.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2LB Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

100

113

In the current month, 2LB has received 25 Buy Ratings, 66 Hold Ratings, and 1 Sell Ratings. 2LB average Analyst price target in the past 3 months is 6.85.

Each month's total comprises the sum of three months' worth of ratings.

2LB Financial Forecast

2LB Earnings Forecast

Next quarter’s earnings estimate for 2LB is -€0.12 with a range of -€0.15 to -€0.09. The previous quarter’s EPS was -€0.15. 2LB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2LB has Performed in-line its overall industry.

2LB Sales Forecast

Next quarter’s sales forecast for 2LB is €69.42M with a range of €61.61M to €77.55M. The previous quarter’s sales results were €74.20M. 2LB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2LB has Performed in-line its overall industry.

2LB Stock Forecast FAQ

What is DE:2LB’s average 12-month price target, according to analysts?

Based on analyst ratings, Iovance Biotherapeutics Inc’s 12-month average price target is 6.85.

What is DE:2LB’s upside potential, based on the analysts’ average price target?

Iovance Biotherapeutics Inc has 106.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Iovance Biotherapeutics Inc a Buy, Sell or Hold?

Iovance Biotherapeutics Inc has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 3 hold ratings and 1 sell ratings.

What is Iovance Biotherapeutics Inc’s share price target?

The average share price target for Iovance Biotherapeutics Inc is 6.85. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €13.69 ,and the lowest forecast is €1.71. The average share price target represents 106.19% Increase from the current price of €3.32.

What do analysts say about Iovance Biotherapeutics Inc?

Iovance Biotherapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Iovance Biotherapeutics Inc?

To buy shares of DE:2LB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Iovance Biotherapeutics (2LB) Stock Forecast & Price Target

2LB Analyst Ratings

2LB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Iovance Biotherapeutics

2LB Analyst Recommendation Trends

2LB Financial Forecast

2LB Earnings Forecast

2LB Sales Forecast

2LB Stock Forecast FAQ

Detailed List of Analyst Forecasts